

ongoing trials - trial from www.clinicaltrials.gov

Standardizing Treatments for Pulmonary Exacerbations - Aminoglycoside Study - Phase 4 - Not yet recruiting

Code: NCT05548283 **Year:** 2022 **Date:** February 1, 2023

Author: Chris Goss|University of
Washington|Medical University of South
Carolina|Cystic Fibrosis Foundation|Seattle
Children's Hospital

Study design (if review, criteria of inclusion for studies)

Interventional - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment

Participants

Cystic Fibrosis|Cystic Fibrosis Pulmonary Exacerbation - 6 Years and older (Child, Adult, Older Adult)

Interventions

Drug: Beta-lactam antibiotic|Drug: Aminoglycoside

Outcome measures

Absolute Change in FEV1 % Predicted at Week 4 in Aminoglycoside (AG) Study|Incidence of Adverse Events (AEs) in Aminoglycoside (AG) Study Intervention Arms|Absolute Change in CFRSD-CRISS Score at Week 4 in Aminoglycoside (AG) Study

<https://ClinicalTrials.gov/show/NCT05548283>

Keywords

Adolescent; Adult; Aminoglycosides; Anti-Bacterial Agents; Bacterial Infections; Drug Administration Schedule; Infection; Netilmicin; pharmacological_intervention; Pneumonia; Pseudomonas aeruginosa; Pseudomonas; Respiratory Tract Diseases; Respiratory Tract Infections; Tobramycin; Exacerbation;